<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="531">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04718467</url>
  </required_header>
  <id_info>
    <org_study_id>JSVCT107</org_study_id>
    <nct_id>NCT04718467</nct_id>
  </id_info>
  <brief_title>Phase IIb Clinical Trial of Recombinant Novel Coronavirus Pneumonia (COVID-19) Vaccine (Sf9 Cells)</brief_title>
  <official_title>A Single-center, Randomized, Double-Blinded, Placebo-Controlled, Phase Ⅱb Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells), in the Subjects From Healthy Aged 18 to 85 Years Old</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Province Centers for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jiangsu Province Centers for Disease Control and Prevention</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase Ⅱb, single-center, randomized, double-blind, placebo-controlled study, to&#xD;
      evaluate the immunogenicity and safety of the recombinant COVID-19 vaccine (Sf9 cells) in the&#xD;
      subjects from healthy adults and elderly adults aged 18 years and above (aged 18-59 and 60-85&#xD;
      years) with immunization procedures 0, 21, 42 days and doses 40μg.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase Ⅱb, single-center, randomized, double-blind, placebo-controlled study, to&#xD;
      evaluate the immunogenicity and safety of the recombinant COVID-19 vaccine (Sf9 cells) in the&#xD;
      subjects from healthy adults and elderly adults aged 18 years and above (aged 18-59 and 60-85&#xD;
      years) . The phase Ⅱb clinical trials designed two research group, including adults group&#xD;
      (aged 18-59 years) and elderly adults group (aged 60-85 years). Each group including 2000&#xD;
      participants. Vaccination or placebo group will be randomly assigned to receive in a 3:1&#xD;
      ratio, 4000 in total.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2021</start_date>
  <completion_date type="Anticipated">March 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of adverse reaction (AR)</measure>
    <time_frame>0 to 7 days after each dose</time_frame>
    <description>The incidence of adverse reaction (AR)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The incidence of Adverse Events of Special Interest (AESI)</measure>
    <time_frame>from day 0 to day 60 after last dose</time_frame>
    <description>The incidence of Adverse Events of Special Interest (AESI)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of adverse events (AE)</measure>
    <time_frame>from day 0 to day 30 after last dose</time_frame>
    <description>The incidence of adverse events (AE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of grade 3 adverse events (AE)</measure>
    <time_frame>from day 0 to day 30 after last dose</time_frame>
    <description>The incidence of grade 3 adverse events (AE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of severe adverse events (SAE)</measure>
    <time_frame>Month 12 after the whole process of vaccination</time_frame>
    <description>The incidence of severe adverse events (SAE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean (GMT) of specific antibody</measure>
    <time_frame>day 30, day 60, month 6, month 12 after last dose</time_frame>
    <description>Geometric mean (GMT) of specific antibody against Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV-2) Spike protein Receptor-binding domain(S-RBD) protein (ELISA) in immunogenicity subgroup.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean (GMT) of anti-SARS-CoV-2-specific neutralizing antibodies</measure>
    <time_frame>day 30, day 60, month 6, month 12 after last dose</time_frame>
    <description>Geometric mean (GMT) of anti-SARS-CoV-2-specific neutralizing antibodies (euvirus and pseudovirus-neutralizing assays)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The positive conversion rate of S-RBD protein-specific antibody</measure>
    <time_frame>day 30, day 60, month 6, month 12 after last dose</time_frame>
    <description>The positive conversion rate of S-RBD protein-specific antibody (ELISA) against SARS-CoV-2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean fold increase (GMI) of S-RBD protein-specific antibody</measure>
    <time_frame>day 30, day 60, month 6, month 12 after last dose</time_frame>
    <description>Geometric mean fold increase (GMI) of S-RBD protein-specific antibody (ELISA) against SARS-CoV-2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The positive conversion rate of anti-SARS-CoV-2 specific neutralizing antibody</measure>
    <time_frame>day 30, day 60, month 6, month 12 after last dose</time_frame>
    <description>The positive conversion rate of anti-SARS-CoV-2 specific neutralizing antibody (euvirus and pseudovirus neutralization test)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean fold increase (GMI) of anti-SARS-CoV-2 specific neutralizing antibodies</measure>
    <time_frame>day 30, day 60, month 6, month 12 after last dose</time_frame>
    <description>Geometric mean fold increase (GMI) of anti-SARS-CoV-2 specific neutralizing antibodies (eucivirus and pseudovirus neutralization assays)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>adults group (aged 18-59 years) &amp; vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>three doses of 40μg Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21, 42.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>adults group (aged 18-59 years) &amp; placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>three doses of placebo at the schedule of day 0, 21, 42.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>elderly adults group (aged 60-85 years) &amp; vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>three doses of 40μg Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21, 42.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>elderly adults group (aged 60-85 years) &amp; placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>three doses of placebo at the schedule of day 0, 21, 42.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant COVID-19 vaccine (Sf9 cells)</intervention_name>
    <description>Three doses of Recombinant COVID-19 vaccine (Sf9 cells) (40μg) at the schedule of day 0, 21, 42.</description>
    <arm_group_label>adults group (aged 18-59 years) &amp; vaccine</arm_group_label>
    <arm_group_label>elderly adults group (aged 60-85 years) &amp; vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Three doses of Placebo (1.0ml) at the schedule of day 0, 21, 42.</description>
    <arm_group_label>adults group (aged 18-59 years) &amp; placebo</arm_group_label>
    <arm_group_label>elderly adults group (aged 60-85 years) &amp; placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18-85 years old&#xD;
&#xD;
          -  Able to understand the content of informed consent and willing to sign the informed&#xD;
             consent.&#xD;
&#xD;
          -  Able and willing to complete all the secluded study process during the whole study&#xD;
             follow-up period (about 14 months).&#xD;
&#xD;
          -  Axillary temperature ≤37.0℃&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Positive serum immunoglobulin M (IgM) and immunoglobulin G (IgG) to the SARS-CoV-2.&#xD;
&#xD;
          -  SARS-CoV-2 nucleic acid testing positive.&#xD;
&#xD;
          -  History of SARS-CoV-2 infection or vaccination&#xD;
&#xD;
          -  A Known History of HIV infection&#xD;
&#xD;
          -  Family history of seizure, epilepsy, brain or mental disease.&#xD;
&#xD;
          -  Participant that has an allergic history to any ingredient of vaccines.&#xD;
&#xD;
          -  Woman who is pregnant, breast-feeding or positive in pregnancy test on day of&#xD;
             enrollment, or is planning to be pregnant during the next 14 months.&#xD;
&#xD;
          -  Any acute fever disease or infections.&#xD;
&#xD;
          -  Have a medical history of SARS.&#xD;
&#xD;
          -  Have serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial&#xD;
             infarction, severe hypertension and not well-controlled.&#xD;
&#xD;
          -  Major chronic illness, such as asthma, diabetes, or thyroid disease, and not&#xD;
             well-controlled.&#xD;
&#xD;
          -  Malignant tumor, activity or have been treated tumor and no clear have cured, or&#xD;
             during the study period is likely to relapse.&#xD;
&#xD;
          -  Hereditary angioneurotic edema or acquired angioneurotic edema.&#xD;
&#xD;
          -  Urticaria in last one year.&#xD;
&#xD;
          -  Asplenia or functional asplenia.&#xD;
&#xD;
          -  Platelet disorder or other bleeding disorder may cause injection contraindication.&#xD;
&#xD;
          -  Faint at the sight of blood or needles.&#xD;
&#xD;
          -  Prior administration of immunodepressant or corticosteroids, antianaphylactics&#xD;
             treatment, cytotoxic treatment in last 6 months.&#xD;
&#xD;
          -  Prior administration of blood products in last 4 months.&#xD;
&#xD;
          -  Prior administration of other research medicines in last 1 month.&#xD;
&#xD;
          -  Prior administration of attenuated vaccine in last 1 month.&#xD;
&#xD;
          -  Prior administration of subunit vaccine or inactivated vaccine in last 14 days.&#xD;
&#xD;
          -  Nearly 7 days, all sorts of acute onset of disease or chronic diseases, such as&#xD;
             receiving anti-tuberculosis treatment, history of asthma.&#xD;
&#xD;
          -  According to the investigator's judgment, due to various medical, psychological,&#xD;
             social or other conditions, it is contrary to the trial protocol or affects the&#xD;
             subjects to sign informed consent.&#xD;
&#xD;
        Exclusion criteria for subsequent doses:&#xD;
&#xD;
          -  Appear systemic allergic reaction, severe allergic reactions.&#xD;
&#xD;
          -  Appear difficult to tolerate more than grade 3 adverse reactions.&#xD;
&#xD;
          -  New discovery or a new happened after the first vaccination does not conform to the&#xD;
             first dose of the inclusion criteria or conform to the first dose of exclusion&#xD;
             criteria, determine whether or not to continue to participate in the study by the&#xD;
             investigators.&#xD;
&#xD;
          -  Investigators think of other reasons.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fengcai Zhu, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jiangsu Provincial Center for Disease Control and Prevention</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fanyue Meng, Doctor</last_name>
    <phone>18915999245</phone>
    <email>mfy19780712@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jiangsu Provincial Center for Diseases Control and Prevention</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Siyue Jia, PhD</last_name>
      <phone>17826065671</phone>
      <email>462371198@qq.com</email>
    </contact>
    <investigator>
      <last_name>Fengcai Zhu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 20, 2021</study_first_submitted>
  <study_first_submitted_qc>January 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>January 21, 2021</last_update_submitted>
  <last_update_submitted_qc>January 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>COVID-19 Vaccine</keyword>
  <keyword>Recombinant vaccine</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

